NeuroPace, Inc. (NPCE)
NPCENASDAQ-GMMedical/Dental Instruments
$12.79
-0.3300 (-2.52%) today
Regular session, Nov 10, 2:03 PM ET
- Market cap
- $439.01m
- P/E
- –
- EPS, last 4 quarters
- $-0.5000
- Dividend yield
- –
- Day range
- $12.65 to $13.34
- 52-week range
- $12.00 to $19.60
- Average volume
- 123.2k
- Previous close
- $13.12
Analysts
4 coveringBuy4 buy, 0 hold, 0 sell
Targets a year out average $19.60, +53.2% from here
Earnings
next estimate $-0.1400Next report Nov 12, 2026
Sep 2025
+45.0%
Dec 2025
+42.9%
Mar 2026
+31.6%
Jun 2026
+5.3%
estimate reported, and the surprise
Financials
| Quarter | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | $35.58m | $26.59m | $22.07m | $22.76m |
| Gross profit | $25.30m | $20.58m | $18.05m | $18.87m |
| Operating income | $378.0k | -$1.77m | -$5.57m | -$5.18m |
| Net income | -$3.50m | -$2.73m | -$6.69m | -$6.20m |
Last four quarters: revenue $106.99m, margin -17.9%, free cash flow -$11.61m
News
8 latest- Treace Medical Concepts (TMCI) Reports Q3 Loss, Tops Revenue EstimatesZacks · 4 days ago
- CVRx (CVRX) Reports Q3 Loss, Lags Revenue EstimatesZacks · 5 days ago
- Alcon (ALC) Surges 6.8%: Is This an Indication of Further Gains?Zacks · 5 days ago
- Neuronetics (STIM) Reports Q3 Loss, Tops Revenue EstimatesZacks · 6 days ago
- Why Is NeuroPace (NPCE) Down 0.4% Since Last Earnings Report?Zacks · Sep 10, 2026
- Here's Why You Should Retain NeuroPace Stock in Your Portfolio for NowZacks · Sep 4, 2026
- NeuroPace Faces an IGE Delay: What the FDA Setback Means for GrowthZacks · Aug 17, 2026
- Is NeuroPace a Buy as Growth Improves but Valuation Stays Elevated?Zacks · Aug 17, 2026
The company
Based in Mountain View, Calif., NeuroPace is a medical device company focused on transforming the lives of people living with epilepsy by reducing or eliminating the occurrence of debilitating seizures. Its novel and differentiated RNS System is the first and only commercially available, brain-responsive platform that delivers personalized, real-time treatment at the seizure source. This platform can drive a better standard of care for patients living with drug-resistant epilepsy and has the potential to offer a more personalized solution and improved outcomes to the large population of patients suffering from other brain disorders.
- Sector
- Health Care
- Industry
- Medical/Dental Instruments
- Exchange
- NASDAQ-GM
- Region
- North America
- Website
- neuropace.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.